【思路迪医药股份(01244.HK):新型放射性核素偶联药物3D1015首次人体给药成功】智通财经APP讯,思路迪医药股份(01244.HK)发布公告,公司首款自主研发的放射性核素偶联药物(RDC)177Lu-PSMA-3D1015(3D1015)已成功完成首例患者给药。本研究旨在评估3D1015用于PSMA阳性转移性去势抵抗性前列腺癌(mCRPC)患者的安全性与初步疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.